A proline ester represented by the following formula (I): ##STR00001## wherein R.sup.1 represents a hydroxy-lower alkyl group, a lower alkoxy-lower alkyl group, or a lower alkoxy-lower alkoxy-lower alkyl group or a pharmaceutically acceptable salt thereof. The proline ester (I) of the present invention and a pharmaceutically acceptable salt thereof are useful as a prodrug of enalaprilat, which is a medicine useful for preventing or treating circulatory diseases such as hypertension, cardiac diseases (e.g., cardiac hypertrophy, cardiac failure, and myocardial infarct), nephritis, and apoplexy. Thus, a drug containing the ester or a salt thereof is preferably formulated to a percutaneous preparation, particularly a patch, from the viewpoint of medicinal activity and use.

Toaeiyo Ltd.

Proline ester and preparation containing the same for percutaneous administration

The invention relates to novel S-nitroso derivatives of ACE inhibitors and to pharmaceutical compositions comprising the S-nitrosothiol derivatives of the invention together with a pharmaceutically acceptable carrier.The invention also relates to methods for treating various pathophysiological conditions including acute myocardial infarction, left ventricular dysfunction without overt heart failure, hypertension, pulmonary hypertension, congestive heart failure, angina pectoris, vascular thrombosis, Raynauds syndrome, scleroderma, toxemia of pregnancy, acute renal failure, diabetic nephropathy, and renal artery stenosis, and to methods of inhibiting ACE and effecting vasodilation comprising administering the S-nitrosothiol derivatives of the ACE inhibitors of the invention to an animal.

Brigham &amp; Women's Hospital

S-nitroso derivatives of hydrazinoacetic acids, 1-[(acylthio and (mercapto)-1-oxoalkyl]-1,2,34-Tetrahydroquinoline-2-carboxylic acids and alanyl prolines and isoquinolines

The present invention relates to methods of using a proline/arginine-rich peptide such as PR11 or PR39 for increasing cardiac mass or performance and in the treatment of heart failure.

Trustees of Dartmouth College

Method for increasing cardiac mass and performance

Zofenopril, fosinopril, (S)-1-[6-amino-2-[[hydroxy (4-phenylbutyl) phosphinyl]oxy]-1-oxohexyl]-L-proline or a pharmaceutically acceptable salt thereof alone or in combination with a thrombolytic, antiarrhythmic, or antifibrillatory agent is employed to reduce pre-and post- ischemic myocardial arrhythmias and fibrillations as well as reducing arrhythmias associated with congestive heart failure.

heart failure/prolina

Proline ester and preparation containing the same for percutaneous administration

S-nitroso derivatives of hydrazinoacetic acids, 1-[(acylthio and (mercapto)-1-oxoalkyl]-1,2,34-Tetrahydroquinoline-2-carboxylic acids and alanyl prolines and isoquinolines

Method for increasing cardiac mass and performance

Method of reducing pre-and post-ischemic myocardial arrhythmias and fibrillation

O mais completo banco de dados de ervas medicinais apoiado pela ciência